Exploring the Potential Drug Target and Biomarker for COL1A2-AS1: Unveiling the Intrinsic Capabilities of this Protein

Target Name: COL1A2-AS1

NCBI ID: G101927525

COL1A2-AS1

Other Name(s): TCONS_00013888 | COL1A2 antisense RNA 1 | lncRNA8975-1

Exploring the Potential Drug Target and Biomarker for COL1A2-AS1: Unveiling the Intrinsic Capabilities of this Protein

The protein COL1A2-AS1 (Tcons00013888) has been identified as a potential drug target and biomarker for various diseases. Its unique structure and various post-translational modifications (PTMs) have piqued the interest of researchers, and its functions continue to be unraveled. In this article, we will delve into the story of COL1A2-AS1, its structural features, and its potential as a drug target and biomarker.

Structure and Function

COL1A2-AS1, also known as Tcons00013888, is a 193-kDa protein that is expressed in various tissues, including epithelial, hematopoietic, and nervous cells. It is a member of the transforming growth factor beta (NF-kappa) signaling pathway, which is a well-established regulator of cell growth, differentiation, and survival. The protein plays a crucial role in the regulation of cell adhesion, migration, and the formation of tissues and organs during development.

COL1A2-AS1 has several unique features that make it an attractive drug target and biomarker. Its first and last exons are farnesylated, which is a well-established mark of protein stability and may influence its stability and interactions with other proteins. Additionally, COL1A2-AS1 has a unique N-terminal region that is rich in electrostatic potential and has been implicated in various cellular processes, including cell adhesion, migration, and the regulation of ion channels.

Expression and Localization

COL1A2-AS1 is highly expressed in various tissues, including the skin, gut, lung, and brain. Its expression is also known to be regulated by various factors, including Wnt, NF-kappa, andNotch. In addition, COL1A2-AS1 has been shown to be expressed in various types of cancer, including lung, breast, and ovarian cancer. This suggests that targeting this protein may be a promising strategy for the development of cancer therapies.

Post-Translational Modifications

COL1A2-AS1 has several post-translational modifications (PTMs), including phosphorylation, ubiquitination, and citrinization. These modifications have been implicated in various cellular processes, including cell adhesion, migration, and the regulation of ion channels. Additionally, COL1A2-AS1 has a unique HN-FY domain that is known to be involved in protein-protein interactions and may influence its stability and interactions with other proteins.

Drug Target Potential

The potential drug target for COL1A2-AS1 is its unique structure and various post-translational modifications. The protein's first and last exons are farnesylated, which may influence its stability and interactions with other proteins. Additionally, the N-terminal region of COL1A2-AS1 is rich in electrostatic potential and has been implicated in various cellular processes.

Biomarker Potential

COL1A2-AS1 has been shown to be expressed in various types of cancer, including lung, breast, and ovarian cancer. This suggests that targeting this protein may be a promising strategy for the development of cancer therapies. Additionally, the protein's unique structure and various post-translational modifications make it an attractive biomarker for various diseases.

Conclusion

In conclusion, COL1A2-AS1 is a unique protein with various features that make it an attractive drug target and biomarker. Its first and last exons being farnesylated, rich N-terminal region, and unique structure are likely to be the basis for its potential as a drug target. Further research is needed to fully understand the functions of COL1A2-AS1 and its potential as a drug

Protein Name: COL1A2 Antisense RNA 1

The "COL1A2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COL1A2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets